Aim: Genotyping ofastroviruses isolated from children with acute enteric infection (AEI) on the territory of Nizhny Novgorod in 2006 - 2011.
Materials And Methods: Samples of feces from children hospitalized in intestine infection department of a Nizhny Novgorod infectious diseases hospitals served as study material. Astroviruses were detected by reverse transcription polymerase chain reaction method. Astrovirus genotypes were determined based on phylogenetic analysis of nucleotide sequence of genome fragment coding capsid protein.
Results: During examination of 5759 children with AEI from July 2006 to June 2011 astroviruses were detected in 2.6% of cases, and in 2010 - 2011 the frequency of astrovirus detection (5.19%) was significantly higher than in the previous epidemic seasons and the average based on the whole observation period. Genotyping of the detected astroviruses showed that genotype 1, 2, 3, 4, 5 astroviruses circulated on the territory of Nizhny Novgorod with predomination ofgenotype 1. Genotype 1 astroviruses are presented by genetic lineages 1a, 1b, 1d with predomination of lineage la. From the start of 2010 all the detected isolates from genetic lineage la belonged to a single new sublineage - 1a-2010. The second by quantity of detected isolates were genotype 5 astroviruses identified for the first time in Nizhny Novgorod in July 2010. Genotype 2, 3 and 4 astroviruses were detected in isolated cases.
Conclusion: Activation of astrovirus circulation in the population of Nizhny Novgorod that was shown by a significant increase of frequency of their detection in children with AEI in 2010 - 2011 epidemic season with the highest probability was caused by appearance of genotype 5 astroviruses, that had not previously been detected in this territory and other territories of Russian Federation.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Ceftobiprole for Treatment of Complicated Bacteremia.
N Engl J Med
October 2023
From the Division of Infectious Diseases, Duke University (T.L.H., N.A.T., V.G.F.), and Duke Clinical Research Institute (T.L.H., V.G.F.) - both in Durham, NC; the Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (S.E.C.); the Division of Infectious Diseases, Department of Medicine, University of California, San Francisco, San Francisco (S.B.D.); the Division of Infectious Diseases, Department of Medicine, Denver Health, Denver (T.C.J.); Tufts Medicine and Tufts University School of Medicine, Boston (H.W.B.); Zaycev V.T. Institute of General and Emergency Surgery of the National Academy of Medical Sciences of Ukraine, Kharkiv (O.P.), Regional Clinical Hospital, Ivano-Frankivsk Regional Council, Ivano-Frankivsk (I.T.), and Dnipropetrovsk I.I. Mechnikov Regional Clinical Hospital, Dnipro (S.K.) - all in Ukraine; Eurohospital Plovdiv, Plovdiv (B.A.), and University Multiprofile Hospital for Active Treatment and Emergency Medicine "N.I. Pirogov," Clinic of Purulent-Septic Surgery, Sofia (I.P.) - both in Bulgaria; LTD Academician Vakhtang Bochorishvili Clinic, Tbilisi, Georgia (M.M.); N.I. Pirogov City Clinical Hospital No. 1, Moscow (A.A.); the Department of Medicine and Division of Infectious Diseases, Centro de Educación Médica e Investigaciones Clínicas, Buenos Aires (M.E.S.); Basilea Pharmaceutica International, Allschwil, Switzerland (M.A.G., M.E., K.H., D.I., M.J., M.S., J.S.); and the Institute for Medical Microbiology, Immunology, and Hygiene, Medical Faculty and University Hospital Cologne, University of Cologne, and the German Center for Infection Research, Partner Site Bonn-Cologne - both in Cologne, Germany (H.S.).
Background: Ceftobiprole is a cephalosporin that may be effective for treating complicated bacteremia, including methicillin-resistant .
Methods: In this phase 3, double-blind, double-dummy, noninferiority trial, adults with complicated bacteremia were randomly assigned in a 1:1 ratio to receive ceftobiprole at a dose of 500 mg intravenously every 6 hours for 8 days and every 8 hours thereafter, or daptomycin at a dose of 6 to 10 mg per kilogram of body weight intravenously every 24 hours plus optional aztreonam (at the discretion of the trial-site investigators). The primary outcome, overall treatment success 70 days after randomization (defined as survival, bacteremia clearance, symptom improvement, no new bacteremia-related complications, and no receipt of other potentially effective antibiotics), with a noninferiority margin of 15%, was adjudicated by a data review committee whose members were unaware of the trial-group assignments.
Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies.
Lancet Haematol
October 2019
Bayer AG, Wuppertal, Germany.
Background: Rivaroxaban has been shown to be efficacious for treatment of venous thromboembolism in adults, and has a reduced risk of bleeding compared with standard anticoagulants. We aimed to develop paediatric rivaroxaban regimens for the treatment of venous thromboembolism in children and adolescents.
Methods: In this phase 2 programme, we did three studies to evaluate rivaroxaban treatment in children younger than 6 months, aged 6 months to 5 years, and aged 6-17 years.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!